★ Metabolic Longevity

AICAR

Metabolic Longevity · 50mg × 10 vials

AICAR tricks the cell into believing it has burned through its energy reserves, even when it has not, and AMPK responds by switching the metabolism from storage mode to burn mode.

✓ 99%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support
📋 Certificate of Analysis Request the third-party COA via Telegram
Quick Start
🧪
Format
Injectable (reconstituted) · 50mg × 10 vials
🎯
Who it's for
endurance goals
💉
How it's run
50 mg (one full 50 mg vial) subcutaneous, pre-workout
When you'll notice
endurance shift 2-3 weeks; acute pre-workout fat-ox signal same-day
Pricing
$160from · kit of 10
~2 week delivery
+ $40 ship (free $1k) · singles $20 (free $500)
50mg × 10 vials$160
Order / Consult on Telegram →
0 hr (IV plasma; SubQ slightly longer); intracellular ZMP signal persists several hours
Half-life
4-8 wk on / 2-4 wk off
Cycling
endurance shift 2-3 weeks
First effects
metabolic-longevity
Class
Overview

What Is AICAR?

AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, also called acadesine or AICA-riboside) is a small molecule, not a peptide. It is a cell-permeable nucleoside that, once inside the cell, is phosphorylated by adenosine kinase into ZMP (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl-5'-monophosphate), a structural mimic of AMP. ZMP allosterically activates AMPK (AMP-activated protein kinase), the cell's master fuel-sensing enzyme, without actually changing the cellular AMP/ATP ratio. In plain language: AICAR tricks the cell into believing it has burned through its energy reserves, even when it has not, and AMPK responds by switching the metabolism from storage mode to burn mode. Downstream of AMPK activation: ACC (acetyl-CoA carboxylase) gets phosphorylated and shut down, which releases malonyl-CoA inhibition of CPT1 and unlocks fatty acid transport into mitochondria for oxidation; GLUT4 translocates to skeletal muscle membrane and pulls glucose out of the bloodstream insulin-independently; PGC-1α is induced and drives mitochondrial biogenesis; mTOR is suppressed and autophagy is upregulated. The signature finding came from Narkar, Downes, Evans et al. in Cell 2008 ("AMPK and PPARδ agonists are exercise mimetics"), where sedentary mice given AICAR for 4 weeks gained 44% endurance on a treadmill versus untreated controls without doing a single workout. That paper is what gave the compound its "exercise in a pill" tag and is also what got AICAR added to the WADA prohibited list in 2011. The compound has formal human clinical history as acadesine in cardiac and renal ischemia-reperfusion trials (RED-CABG, ACTT-CABG, Phase 3 in CABG surgery), where IV infusion reduced infarct size and improved post-op outcomes but did not hit the primary endpoint. Outside that surgical context, no formal weight-loss or performance trials in humans exist.

Protocols

Typical dose ranges by experience level — educational reference. Message us and we tailor it to you.

Protocol50 mg (one full 50 mg vial) subcutaneous, pre-workout
Frequency3-5× per week, dosed 30-60 minutes before training
Duration4 weeks on, 2 weeks off before assessing whether to push to higher frequency or daily dosing

AICAR has a short half-life so dose timing matters more than total weekly dose at the beginner level. Pre-workout pulse dosing produces the cleanest acute fat-oxidation and endurance read; non-training days can be skipped at this tier. Reconstitute 50 mg vial with 2 ml BAC = 25 mg/ml, so 50 mg = 2 ml = 200 IU on a U-100 syringe. Inject 30-60 min before training.

Protocol50-100 mg/day subcutaneous, daily
Frequency1× per day on training days (pre-workout), 1× per day fasted morning on rest days
Duration6-8 weeks on, 2-4 weeks off

This is the community working range. Daily dosing produces a continuous AMPK signal versus the pulsed pre-workout-only approach at the beginner tier. Endurance gains become measurable by week 2-3 (longer time-to-exhaustion at the same heart rate), fat-composition shifts visible at week 4-6. Stack with SLU-PP-332 or MOTS-c is common at this tier. Watch resting HR and sleep; reduce dose or pull PM injection forward if either degrades.

Protocol100-500 mg/day subcutaneous, split 2-3× across the day
Frequency2-3× per day
Duration6-8 weeks on, 4 weeks off, 2-3 cycles per year

Advanced protocols are stacked, not run solo. The Mito Stack (AICAR + MOTS-c + SLU-PP-332) is the most common community protocol at this tier. Cycling is non-negotiable at this dose range; AMPK desensitization signal is documented preclinically with chronic dosing. WADA testing detection window at these doses is several weeks; any customer subject to drug testing should not run AICAR at all.

What To Expect
endurance shift 2-3 weeks
noticeable change
acute pre-workout fat-ox signal same-day
noticeable change
Side Effects

Straight talk — what people actually report, and what the studies measured.

What users report
From forums, Discord & TikTok
  • Endurance improvement: most-reported positive effect, described as easier breathing during cardio, longer time-to-exhaustion, lower perceived effort at the same heart rate. Typically measurable by week 2-3.
  • Fat composition shifts: visible by week 4-6 at intermediate doses, more pronounced when stacked with MOTS-c or SLU-PP-332
  • Injection site reactions: redness, transient lump, occasional warmth; manageable with site rotation
  • Mild fatigue or "metabolic shift" feeling weeks 1-2: typically resolves by week 3, described as the body adjusting to higher fat oxidation
  • Hunger shifts: usually increased appetite (mitochondrial demand goes up) at intermediate-to-advanced doses; some users report no change
  • Sleep: usually neutral or improved, occasional reports of vivid dreams or lighter sleep early in cycle
  • Joint aches: occasional reports, possibly related to uric acid push (gout risk), rare but real
  • Mild GI: occasional nausea at higher doses, usually resolves with food
What the studies show
Measured in clinical trials
  • IV acadesine in CABG surgery trials (RED-CABG, Phase 3, n>2000): no significant excess in major adverse events vs placebo; hypotension and mild GI signal reported but not statistically separated from background surgical AEs. Did not hit primary endpoint of reduced major adverse cardiac events.
  • Renal: mild transient transaminase elevation reported in some Phase 2 acadesine trials, no clinically meaningful renal injury at studied IV doses
  • Hyperuricemia: AICAR metabolites push purine flux through xanthine oxidase, raising serum uric acid. Documented in clinical trials and a real signal at chronic dosing.
  • No formal human trial data on weight loss, endurance, or longevity outcomes from subcutaneous community dosing exists.
The Research

Peer-reviewed studies and clinical guidelines — tap any to read the source.

PubMedNarkar VA, Downes M, Evans RM et al. AMPK and PPARδ agonists are exercise mimetics. Cell 2008

the original "exercise in a pill" paper, 44% endurance gain in sedentary mice on AICAR for 4 weeks

Read study ↗
PubMedCorton JM et al. 5-aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells, Eur J Biochem 1995

foundational paper on AICAR as the canonical AMPK activator

Read study ↗
PubMedSanders MJ et al. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade, Biochem J 2007

ZMP allosteric activation mechanism

Read study ↗
PubMedCuthbertson DJ et al. 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside acutely stimulates skeletal muscle glucose uptake in healthy men, Diabetes 2007

one of the few human studies; IV AICAR raised glucose uptake in skeletal muscle

Read study ↗
Clinical guidelinesNewman MF et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial, JAMA 2012

Phase 3 IV acadesine in cardiac surgery, missed primary endpoint

Read study ↗
Clinical guidelinesWADA Prohibited List — AICAR classified as a metabolic modulator banned in and out of competition since 2011Read study ↗
+ 3 more studies & references
From The Community

Aggregated sentiment from public forums & socials — real-world reports, not individual endorsements.

Rr/Peptides AICAR threa

Endurance improvement: most-reported positive effect, described as easier breathing during cardio, longer time-to-exhaustion, lower perceived effort at the same heart rate. Typically measurable by week 2-3.

Rr/biohacking discussio

Fat composition shifts: visible by week 4-6 at intermediate doses, more pronounced when stacked with MOTS-c or SLU-PP-332

TThe Peptide Catalog —

Injection site reactions: redness, transient lump, occasional warmth; manageable with site rotation

PPeptideDeck — AICAR me

Mild fatigue or "metabolic shift" feeling weeks 1-2: typically resolves by week 3, described as the body adjusting to higher fat oxidation

LLongevity

Hunger shifts: usually increased appetite (mitochondrial demand goes up) at intermediate-to-advanced doses; some users report no change

Rr/Peptides AICAR threa

Sleep: usually neutral or improved, occasional reports of vivid dreams or lighter sleep early in cycle

Common Questions
SubQ (community standard) or IV (clinical/research). Oral bioavailability is poor (~5%), so injection is the only route that produces a meaningful signal..
endurance shift 2-3 weeks; acute pre-workout fat-ox signal same-day
Most users run a recovery (PCT) protocol after a cycle to restore natural production and hold onto gains. Message us for the standard protocol.
A popular pairing is AICAR + SLU-PP-332 (exercise mimetic dual). See the Protocols section, or ask us for a stack built around your goal.
Yes. Every batch is third-party lab tested — request the COA on Telegram and we send it over.
Safety & Contraindications

Hard stops

  • Active gout or hyperuricemia (AICAR raises uric acid through purine metabolism, real signal)
  • Active cardiac arrhythmia or unstable cardiovascular disease (AMPK activation in stressed cardiac tissue has theoretical fuel-switch concerns similar to SLU-PP-332)
  • Pregnancy or actively trying to conceive (no reproductive safety data)
  • Pediatric use (developmental AMPK signaling is not a target for chronic external modulation)
  • Anyone subject to USADA/WADA or other competitive drug testing (banned substance, detectable for weeks)
  • Active malignancy (AMPK activation is a complex tumor-biology signal; in some contexts pro-cancer, in others anti-cancer, the literature is mixed enough to warrant avoidance)

Caution flags

  • History of gout, kidney stones, or hyperuricemia
  • Severe renal impairment (eGFR <30)
  • Insulin-dependent diabetes (AICAR can lower blood glucose; coordinate with insulin dosing)
  • History of cardiac arrhythmia even if currently controlled
  • Anyone on metformin (both activate AMPK; not a hard conflict but no need to double up the signal at top doses)
  • Severe sleep disorder (compound can disrupt sleep at top doses, similar to other AMPK activators)

Stacking conflicts

  • No documented hard conflicts. The Mito Triple stack (AICAR + SLU-PP-332 + MOTS-c) is the most aggressive combination community runs, and the mechanisms layer rather than compete.
  • Avoid stacking with stimulants at top doses (HR effect can compound)
  • Metformin overlap is mechanistic but not dangerous; just redundant at high AICAR doses
Is It Right For You?

✓ Good fit

  • endurance goals
  • longevity stack builders
  • post-injury cardio rebuild
  • metabolic-flexibility focus
  • training-plateau breakers
  • customers running SLU-PP-332 or MOTS-c who want the third leg of the stack
  • GLP-1 plateau breakers

✗ Not a fit

  • competitive athletes subject to testing
  • active gout/hyperuricemia
  • cardiovascular disease
  • pregnancy/conception window
  • customers wanting a substitute for training rather than an amplifier
  • customers who need US-stock fast-delivery products

Administration & Storage

Route: SubQ (community standard) or IV (clinical/research). Oral bioavailability is poor (~5%), so injection is the only route that produces a meaningful signal.

Injection site: abdomen or outer thigh, rotate sites. Some users split SubQ across two sites at higher doses to reduce local irritation.

Storage: refrigerated, ~28 days after reconstitution. Light-sensitive, store in original vial.

Notes: Plasma half-life is short (~1 hr), so pre-workout dosing (30-60 min before training) is the most common protocol. Some advanced users split daily dose into 2 injections (AM + pre-workout) to maintain a steadier ZMP signal across the day. Reconstitute with bac water, swirl gently, do not shake. Powder should dissolve fully within a minute. If running 100 mg/day, the cleanest path is a 50 mg/ml recon (1 ml BAC into 50 mg vial) so one injection covers the daily dose at 200 IU.

All products sold for research purposes only. Not for human or animal consumption. Must be 18+ to purchase. By placing an order you confirm compliance with all applicable local laws and regulations.